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Bone marrow cavities fill up with fat in 
mice lacking the transcription factor EBF-1 
(early B cell factor-1), according to data 
from Mark Horowitz (Yale University 
School of Medicine, New Haven, CT).
The evolutionarily conserved EBF 
transcription factors (EBF-1–4) are required 
for the development of olfactory neurons 
and B cells. EBF-1 also promotes fat cell 
(adipocyte) differentiation when overexpressed 
in preadipocyte cell lines, but the mecha-
nism—and in vivo significance—of this 
finding was unclear.
To investigate the role of EBF-1 in fat 
formation, Horowitz and colleagues ex-
amined mice lacking the transcription 
factor. In addition to having no B cells, 
the mice had fat in all the wrong places. 
Subcutaneous fat was almost entirely 
missing, possibly explaining their previ-
ously described wasted appearance. The 
mice instead had fat where their bone 
marrow should be.
Excess fat wasn’t their only problem. 
The EBF-1–deficient mice also had in-
creased bone mass due to an overabundance 
of osteoblasts. The combined fat–bone 
phenotype prompted Horowitz to suggest 
that EBF-1 might regulate gene expression 
in a common adipocyte–osteoblast precursor 
cell, as these cells are known to arise from a 
common progenitor. But this hunch is 
difficult to test. Unlike in B cell develop-
ment, few markers have been identified to 
distinguish osteoblast precursor cells at 
various stages of differentiation. In this respect, 
says Horowitz, “bone biologists are 15 years 
behind immunologists.”
The only targets of EBF-1 identified 
thus far are those involved in B cell devel-
opment. One of those targets, the B cell–
specific transcription factor encoded by 
Pax5, is also required for bone maintenance. 
But in bone, the relationship between 
EBF-1 and Pax5 is more complicated, as 
the absence of Pax5 causes severe bone 
loss—the opposite of the defect caused by 
EBF-1 deficiency. 
Reference: Horowitz, M.C., et al. 2005. Immunol. Rev. 
208:141–153.
Low estrogen—during menopause in women or induced by ovary 
removal in rodents—causes osteoporosis. Roberto Pacifici (Emory 
University School of Medicine, Atlanta, GA) has put the blame 
for this bone loss squarely on T cells and, at the meeting, he 
provided corroborating evidence. But new data from Reinhold 
Erben (University of Veterinary Medicine, Vienna, Austria) 
seems to exonerate these cells.
Perhaps the strongest evidence that T cells cause bone loss 
when estrogen is in short supply comes from T cell–deficient 
(“nude”) mice. In past studies, Pacifici and colleagues showed that 
nude mice—unlike wild-type mice—do not develop osteoporosis when their ovaries are removed. Bone loss 
kicks in when T cells are transferred into the mice. This effect depends on T cell production of the cytokine 
TNF, which causes stromal cells to produce growth factors that stimulate bone-resorbing osteoclasts.
Bone loss is also a symptom of T cell–driven autoimmune diseases, such as rheumatoid arthritis (RA). And 
the symptoms of RA worsen after childbirth and menopause, when estrogen levels are low, also hinting at a 
possible connection between estrogen, T cells and bone loss. Pacifici’s group has now found that 
ovariectomized mice treated with a T cell–inhibiting drug (Abatacept) have lower levels of circulating TNF and 
are spared the bone loss normally induced by ovary loss. When the drug was discontinued, bone loss resumed.
Erben does not dispute the mouse data, but rather questions their relevance to other species. 
“This may be true for mice,” says Erben. “But whether this model is predictive of human physiology 
is unclear.” Erben’s data showed that thymectomized rats depleted of circulating T cells still 
developed osteoporosis when their ovaries were removed. And the rat, suggests Erben, may be a 
better model of postmenopausal osteoporosis than the mouse. In the rat model, as in humans, 
bone loss is sustained, whereas in mice, bone loss is transient. 
Reference: Weitzmann, M.N. 2006. J. Clin. Invest. 116:1186–1194.
T cells to blame?
Bone loss after ovariectomy is comparable in the presence (left) 
or absence (right) of T cells.
Fat cells (white) accumulate in the 
bone marrow of mice lacking EBF-1 
(bottom).
Does this gene make my bone marrow look fat?
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Osteoclasts that can’t unite
The formation of bone-resorbing osteoclasts requires cell–cell 
fusion between monocyte lineage precursor cells. But little is 
known about how this fusion is regulated and what proteins 
it requires. According to Yongwon Choi (University of Penn-
sylvania, Philiadelphia, PA), fusion among preosteoclasts requires 
a subunit of the vacuolar ATPase (v-ATPase) proton pump—but 
not the proton pumping action of the v-ATPase itself.
Choi and colleagues had previously identified a novel 
isoform of the v-ATPase d2 subunit (d2)—one of the five 
subunits that form the membrane-spanning proton channel—
in a search for genes preferentially expressed in osteoclasts. 
Finding d2 was not surprising, as osteoclasts use plasma mem-
brane v-ATPases to acidify the extracellular space between the 
cell and the bone surface—the first step in bone resorption.
The surprise came, as presented by Choi, when the group 
eliminated d2 from mice. The d2-deficient mice had increased 
bone mass, not because their osteoclasts were defective in 
resorption, but simply because there were too few of them—
at least of the multinucleated sort that digest bone the best. 
The paucity of multinucleated osteoclasts did not reflect a 
block in differentiation, as precursor cells from the d2-less 
mice still developed into mononuclear osteoclasts, which 
retained the normal low-level resorption activity. But without 
d2, the mononuclear cells couldn’t fuse.
The normal mechanism of d2 action remains a mystery. In 
other cell types, v-ATPases are found on intracellular membranes 
where they promote pH-dependent membrane fusion. But, so far, 
a role for v-ATPase subunits in cell–cell fusion has been docu-
mented only in C. elegans. There, a v-ATPase subunit prevents 
the inappropriate fusion of embryonic cells by somehow blocking 
the expression of a fusion-promoting membrane protein. 
Reference: Rho, J., et al. 2002. DNA Cell Biol. 21:541–549.
According to data from Steven Teitelbaum 
(Washington University, St. Louis, MO), 
glucocorticoids (GCs)—the most widely 
used class of antiinflammatory drug—
prevent osteoclasts from rearranging their 
cytoskeletons and thus from digesting 
bone. And without proper osteoclast 
function, bone-building osteoblasts also 
shut down, which might help explain 
the crippling osteoporosis that often 
accompanies long-term steroid therapy.
Prolonged GC therapy impairs normal 
bone remodeling, an ongoing process in 
which osteoclasts dig small pits in bone 
and osteoblasts fill them up with new 
bone. This continual turnover is essential 
to maintain the structural integrity of the 
bone. In patients with GC-induced 
osteoporosis, these pits do not get fully 
filled. The mechanism behind this defect 
was controversial, particularly as treating 
osteoblasts with GCs in vitro actually 
enhances their activity.
GCs might also have an indirect effect 
on osteoblasts, reasoned Teitelbaum, as 
the activity of osteoblasts and osteoclasts 
are tightly linked—an increase or decrease 
in the activity of one cell type prompts a 
parallel change in the other. Teitelbaum 
found that mouse osteoclasts treated 
with the GC dexamethasone failed to 
spread out on bone surfaces and had 
decreased bone-resorbing capacity. This 
dampened osteoclast activity triggered a 
subsequent decrease in bone formation, 
as bone loss was less severe in mice 
whose osteoclasts (but not 
osteoblasts) lack the 
glucocorticoid receptor. Why 
the decrease in osteoblast 
activity ultimately 
outweighed the 
decrease in osteoclast 
activity is not yet clear.
The osteoclast 
defect was traced to a 
block in the activation of 
the GTPases RhoA and Rac, 
which are needed for 
osteoclasts to rearrange their 
actin cytoskeletons and thus 
form a tight seal with bone surfaces. 
GCs blocked the activation of 
GTPases by suppressing the 
phosphorylation of the 
osteoblast-specific guanine nucleotide 
exchange factor Vav3.
In the meantime, these data raise 
potential concerns about the use of 
antiresorptive agents (such as Fosamax) 
to treat osteoporosis. Although these 
agents curb bone loss, they have also 
been reported to decrease bone remodeling, 
which causes brittle, fracture-prone 
bones. “It is not only the amount of bone 
present [that is important],” says Teitelbaum, 
“but also the quality of the bone.” 
Reference: Kim, H.J., et al. 2006. J. Clin. Invest. 
116:2152–2160.
Fusion of preosteoclasts is faulty in the absence of d2 (right).
Osteoclasts on steroids
Glucocorticoids inhibit osteoclast function, which in turn 
impairs osteoblast function.
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Marrow-less mice
A give-and-take between the action of bone-
building osteoblasts and bone-resorbing osteoclasts 
keeps bone mass constant. Both cell types are 
controlled by an array of regulatory proteins, only 
some of which have been identified. One of these 
regulators, described by Laurie Glimcher (Harvard 
Medical School, Boston, MA), suppresses bone-
building activity by marking an osteoblast-specific 
transcription factor for destruction.
Glimcher’s group had previously identified 
the regulator in question—the zinc finger protein 
schnurri-3 (Shn3)—as an adaptor protein 
expressed in CD4+ T helper (Th)-1 cells that 
drives IL-2 expression. But when the group 
eliminated Shn3 from mice, they ran into an 
unexpected problem. “My postdoc, Dallas [Jones], 
was having trouble getting bone marrow from 
the deficient mice,” says Glimcher, “so we took 
an x-ray [to find out why].” The x-ray revealed 
an age-related increase in bone mass so severe 
that, by seven months of age, the mice had 
virtually no marrow left.
The Shn3-deficient mice had bulked-up bones 
due to overly active osteoblasts. Osteoblasts from 
these mice had increased expression of Runx2, 
the preeminent transcription factor that drives 
osteoblast differentiation and function. In normal 
mice, Glimcher showed, Shn3 binds to the 
ubiquitin ligase WWP1. Shn3 and WWP1 then 
team up to ubiquitinate Runx2, tagging it for 
proteasomal degradation.
Normally, osteoclasts get revved up to 
compensate for increased osteoblast activity. 
Why this fails to occur in the absence of 
Shn3 is unclear, as Shn3-deficient osteoclasts 
appeared to function normally. The team is now 
investigating this question. 
Reference: Jones, D., et al. 2006. Science. 312:1223–1227.
Tackling TREM2
Data presented by Marco Colonna (Washington University, St. Louis, 
MO) and Mary Nakamura (UCSF, San Francisco, CA) raised more 
questions about the bone defects in a rare genetic disorder—Nasu-Hakola 
disease—than they answered.
Previous work by Colonna’s group showed that monocytes from 
patients with Nasu-Hakola disease fail to form bone-resorbing osteoclasts 
in vitro, suggesting that TREM2 is required for osteoclast differentiation. 
Nakamura’s new mouse data extended this finding, showing that 
blocking TREM2 with antibodies prevented both the differentiation of 
osteoclast precursors and the resorptive function of mature osteoclasts.
But Colonna’s mouse studies suggest the opposite—precursor cells 
from mice lacking TREM2 differentiated into osteoclasts more efficiently 
than wild-type cells. “The problem [with the antibody data],” says 
Colonna, “is that we don’t know whether the antibody is activating or 
inhibiting [TREM2 signaling].”
Indeed both inhibitory and activating functions for TREM2 have been 
reported. Ligation of TREM2 on brain cells, for example, increases 
phagocytosis. On macrophages, its ligation dampens cytokine production.
The avidity of a ligand for TREM2 might determine whether a positive or 
negative signal is transmitted. The hunt is on for these TREM2 ligands. 
References: Cella, M., et al. 2003. J. Exp. Med. 198:645–651.
Humphrey, M.B., et al. 2006. J. Bone Miner. Res. 21:237–245.
T cells egg on osteoclasts
Inflammatory disease and infection often go hand-in-hand with bone loss. 
Mucosal infection with the parasite Leishmania, for example, can destroy 
bones in the face and palate. Bone destruction in a mouse model of this 
disease, according to Marlon Quinones (University of Texas, San Antonio, TX), is 
triggered by activated CD4+ T cells, which spur on bone-digesting osteoclasts.
CD4+ T cell differentiation is a known determinant of disease outcome 
in mouse models of leishmaniasis. A Th1 response—dominated by the CD4+ 
T cell production of interferon (IFN)-γ—protects against the parasite, 
whereas a Th2 response—dominated by the production of interleukin (IL)-4, 
is associated with susceptibility.
This Th1–Th2 balance, according to 
Quinones, also contributes to infection-
induced bone loss. Mice lacking IFN-γ 
developed local and systemic bone loss 
when infected intradermally with 
Leishmania major, due to a massive 
accumulation of osteoclasts. The 
overabundance of osteoclasts was initiated 
by T cells, as transferring IFN-γ–deficient 
CD4+ T cells into lymphocyte-deficient mice 
triggered bone loss.
Bone destruction did not depend on 
T cell production of the osteoclast growth 
factor RANKL, which contributes to bone 
loss in other diseases, such as rheumatoid 
arthritis. The real culprit, suspects Quinones, 
is IL-17, which was produced in excess by the IFN-γ-deficient T cells and is 
required in other T cell–driven diseases. The group, co-led by Seema Ahuja, is 
now testing their suspicion by blocking IL-17 in the IFN-γ–deficient mice. 
Shn3-deficient mice (right) lack bone marrow.
Leishmania infection triggers bone 
loss in IFN-𝗄–deficient mice.
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